Navigation Links
Laboratory Testing Can Identify Risk of Pre-Term Labor and ,,Delivery ,,

A test for fetal fibronectin can predict whether a pregnant woman is at risk for early labor and delivery. Those at high risk for pre-term births are women with previous pre-term deliveries, those with multiple gestation pregnancy, and those who suffer from diabetes and/or hypertension. The current approach for finding whether a woman will go into premature labor is the use of a clinical scoring system, risk classification, and patient presentation; The marker that can identify at-risk women is fetal fibronectin (fFN).A glycoprotein that is secreted by the fetal membrane and found in the choriodecidual junction, fFN is responsible for cellular adhesions. The level of fFN in the woman's cervicovaginal secretions is highly associated with pre-term labor and pre-term delivery. The fFN immunoassay detects concentrations of fetal fibronectin protein in cervicovaginal fluids; the presence of more than 50 ng/mL is considered positive.

The fFN test has been approved by the U.S. Food and Drug Administration for use as an aid in assessing the risk of pre-term delivery during the routine screening of asymptomatic patients from 22-30 weeks' gestation, and for women with symptoms of pre-term labor from 24-35 weeks' gestation. High-risk asymptomatic patients with a low fFN reading may be advised to continue with additional repeat follow-ups, with a repeat of the test if the patient becomes symptomatic.
'"/>




Page: 1

Related medicine news :

1. Laboratory grown vegetarian meat
2. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
3. Laboratory Heart valve to study Heart diseases
4. NCFAD Nominated As Reference Laboratory for Bird Flu and BSE
5. British Laboratory Certifies Coke as Safe
6. India to Set Up Nicotine-Mapping Laboratory
7. A Laboratory Filtration System Kills 100 Percent Of Dangerous Microbes In Water
8. Erroneous Laboratory Operation May Lead To a Cancer Drug
9. First Vaccine Designed for Africa Cleared for Testing in Humans
10. Testing for blood sugar levels made easier
11. DNA Testing For More Accurate Results
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... 25, 2017 , ... Somnoware, a leading provider of digital ... module. Using this new feature, sleep physicians can now predict the likelihood of ... airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The Somnoware ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in ... a special report in the May issue of Consumer Reports focused on heart health. ... for results achieved during and after coronary bypass and aortic valve replacement procedures. ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... instrument solutions, announces the continuation of its strategic partnership with and platinum sponsorship ... developing nations in the safe and effective management of complex spine deformity cases, ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored with the ... the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I ... improve the lives of the poor and underserved in other parts of the world,” ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
Breaking Medicine Technology: